Sanofi and Regeneron’s immunology juggernaut Dupixent is on the brink of another big new indication after it was recommended by the EMA’s human medicines committee for chr
The US FDA has given accelerated approval for Eli Lilly’s RET inhibitor as a treatment for various RET-altered paediatric cancers, making it the first drug in the class av
In another deal that highlights the pressures facing companies in the digital health sector, Akili Interactive has agreed to go private in a merger with Virtual Therapeuti
The US FDA has approved the first biosimilar version of AstraZeneca/Alexion’s Soliris therapy for paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemi
Asahi Kasei has offered to buy Sweden’s Calliditas Therapeutics for SEK 11.8 billion ($1.1 billion) as part of a plan to expand internationally in healthcare.
The future of Nippon Shinyaku’s Duchenne muscular dystrophy (DMD) therapy Viltepso has been thrown into doubt after it failed a clinical trial designed to upgrade its 2020